MEN1 and acute myeloid leukemia: While several menin inhibitors are in different phases of development with revumenib already US FDA approved in R/R KMT2A-r acute leukemias and more recently NPM1mut AML, ongoing clinical benefits with these agents as monotherapy will be important to evaluate and may turn out to be possibly challenging.